Skip to content
HowShorted

EAGLE PHARMACEUTICALS, INC. short interest in 2023

In 2023, EAGLE PHARMACEUTICALS, INC.'s disclosed short interest ran from 7.44% of shares outstanding on 13 Jan 2023 to 5.37% on 29 Dec 2023, a change of -2.07 percentage points. The year's high was 7.82% on 15 Mar 2023 and its low 4.13% on 29 Sep 2023, averaging 5.59% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 9.50 days on 28 Apr 2023. Full history: EAGLE PHARMACEUTICALS, INC..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024

Aggregate net short position time series for EAGLE PHARMACEUTICALS, INC. in 2023

2023 in figures

Start of year
7.44% (13 Jan 2023)
End of year
5.37% (29 Dec 2023)
Change
-2.07 pp
High
7.82% (15 Mar 2023)
Low
4.13% (29 Sep 2023)
Average
5.59%
Highest days to cover
9.50 (28 Apr 2023)
SEC filings marked
8

Every report in 2023

EAGLE PHARMACEUTICALS, INC. short interest in 2023
SettlementShort interestDays to coverFilings since previous
13 Jan 20237.44%5.98
31 Jan 20236.72%6.65
15 Feb 20236.66%8.09
28 Feb 20236.73%8.44
15 Mar 20237.82%5.35results (8-K)
31 Mar 20237.18%3.4510-K filed
14 Apr 20235.77%5.13
28 Apr 20235.47%9.50
15 May 20235.31%5.0110-Q filed, results (8-K)
31 May 20235.24%5.32
15 Jun 20236.21%3.77
30 Jun 20234.54%1.33
14 Jul 20235.20%4.17
31 Jul 20234.99%6.54
15 Aug 20235.25%3.5910-Q filed, results (8-K)
31 Aug 20234.93%4.79
15 Sep 20235.43%6.20
29 Sep 20234.13%6.43
13 Oct 20234.64%5.35
31 Oct 20234.76%8.04
15 Nov 20234.58%4.22results (8-K)
30 Nov 20234.55%2.04
15 Dec 20235.17%2.48results (8-K)
29 Dec 20235.37%2.54

See also: EAGLE PHARMACEUTICALS, INC.'s full history · most shorted US stocks of 2023 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.